

Global Leader IFF and Microba Reach First Milestone in Treatment Program

- First data package delivered in research partnership with International Flavors & Fragrances Inc. (“IFF”)
- IFF is a US\$31bn NYSE listed (NYSE: IFF) global leader in the food, beverage, biosciences and health sectors
- Discovery project to identify microbiome-based solutions for several allergic conditions
- Multiple microbial therapy leads for asthma and allergic rhinitis identified from Microba’s databank

Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce the first data package has been delivered to International Flavors & Fragrances Inc. (“IFF”) (NYSE: IFF) in a research partnership to discover and develop microbiome-based solutions for multiple forms of allergy.

IFF is an industry leader in food, beverage, biosciences and health sectors with a global footprint and extensive product portfolio. IFF is New York Stock Exchange listed with a US\$31 billion market capitalisation.

This is the first milestone in a joint discovery project which commenced in November 2021 to identify novel allergy treatments by leveraging Microba’s Databank of over 15,000 gut microbiome samples and associated health data.

With around 30-40 per cent of the world’s population being affected by one or more allergiesⁱ, the partnership aims to identify bacterial leads for the treatment of allergies by investigating the relationship between the human gut microbiome and a range of allergic conditions.

The data delivery, identifying multiple microbial therapy leads for asthma and allergic rhinitis, is the first step in a potential longer-term commercial relationship between the parties leveraging Microba’s Therapeutic Platform to develop novel allergy treatments.

Microba’s Chief Scientific Officer, Associate Professor Lutz Krause, said, “our human first, data-driven approach has revealed a number of promising leads, and our work in other indications provides us with confidence that the discovery of these leads with IFF can enable the development of novel microbiome-based therapies.”

This demonstrates Microba’s repeatable, scalable data-driven Therapeutic Platform with the ability to partner with large multinational health and pharmaceutical companies to discover and develop novel monoclonal microbial cell therapies.

This announcement has been authorised for release by the Board.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About International Flavors & Fragrances Inc. (IFF)

At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

ⁱ <https://gaapp.org>